Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve outcomes of patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, acquired resistance inevitably emerges and remains a major challenge. The present study aimed to evaluate the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yuman, Wang, Yuehong, Wu, Linying, Xu, Xuanli, Zhou, Hua, Wang, Qing, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870213/
https://www.ncbi.nlm.nih.gov/pubmed/33592829
http://dx.doi.org/10.1097/MD.0000000000023712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870213/
https://www.ncbi.nlm.nih.gov/pubmed/33592829
http://dx.doi.org/10.1097/MD.0000000000023712

Ejemplares similares